Disability and Workers' Compensation Absences Associated with Major Depressive Disorder and the Overlap with Family Medical Leaves Among United States Employees

Richard A. Brook, MS, MBA¹⁻³; Alek A. Drnach, MS⁴; Ian A. Beren, BS⁵; Nathan L. Kleinman, PhD¹; Tanyatorn Ghanjanasak, DO¹; Eric M. Rosenberg, MA⁴

¹Better Health Worldwide, Newfoundland, NJ. ²The National Payor Roundtable, Glastonbury, CT. ³National Association of Specialty Pharmacy, Washington, DC. ⁴Workpartners, LLC, Pittsburgh, PA.. ⁵Workpartners, LLC, Loveland, CO.

Background

- Major depressive disorder (MDD)¹ is a chronic psychiatric disease:
 - That affects approximately 7.1% of United States (US) adults
 - With 80% of MDD patients reporting difficulties with work, home, or social activities
- The US Family and Medical Leave (FML) Act of 1993² allows eligible employees of covered employers to take unpaid, job-protected leave for specified (person or family) medical reasons with continuation of insurance coverage as if the employee had not taken leave.
 - Once opened, an FML claim remains open for a year
 - Because FML is unpaid, some employees take an overlapping paid leave under their other benefits
- US employee benefits can have a significant impact on business performance, and generally include:
 - Sick Leave (SL) for paid time off, generally without a specific reason
 - Short- and Long-term Disability (STD and LTD, respectively) for non-workrelated injuries/illnesses
 - Workers' Compensation (WC) for work-related injuries/illnesses

Objectives

 This study aims to examine the use of paid leaves and the overlap with non-paid Family and Medical Leaves (FMLs) in US employees with major depressive disorder (MDD).

Study Population


- US employees within the Workpartners Research Reference Database (RRDb) from 2001 to present, which contains employees in all states:
 - Medical and pharmaceutical claims for over 5.5 million employees and dependents
 - Enhanced employee demographics (including race and marital status)
 - Job-related employee information (salary, job type, full/part-time status, exempt/non-exempt status)
 - Claims with absence durations and payments for employee populations eligible for STD=1.3 million, LTD=1.2 million, WC=2.8 million.
 - Dental (21.2 million) and vision claims (12.0 million)
 - Self-assessed presenteeism records for 185,094 employees (579,042 total records)
- Workpartners RRDb has been used for research on conditions including:
 - Disability and workers' compensation trends for employees with mental disorders and substance use disoders³, cancer⁴, and eye disorders⁵
 - The impact on employees of conditions such as rheumatoid arthritis,⁶ bipolar disorder^{7,8}, cancer⁴, diabetes⁹, and eye disorders^{5,9}, and multiple sclerosis¹⁰
 - Caregiver research on the impact of major depressive disorder with and without suicidal ideation¹¹, pediatric asthma¹², epilepsy¹³, cancer¹⁴, and multiple sclerosis¹⁵


Methods

- Retrospective analysis of US employees with two years of post MDD diagnosis.
- FML, STD, LTD, and WC eligibility between 2018 and 2022.
- Employees with MDD were identified and indexed by the initial ICD-10 code claims.
- FML utilization based on employer human resource data.
- The control group was a 3:1 random subset of employees without MDD, with an index date randomly assigned between 2018 and 2020.
- All employees had ≥2 years continuous eligibility following their index date.
- The following outcomes were evaluated and reported:
 - FML claims opened in the year after the index date
 - STD, LTD, and WC leaves initiated during the first 2 years after the index date
 - STD, LTD, and WC leaves initiated during the year following an FML leave to measure overlap
- All reported comparisons P < 0.01.

Results

- There were 7888 employees with MDD and 23,586 controls.
- Almost 3x (277%) the FML claims were filed by those with MDD in the year following the index date. 1806 (22.9%) by those with MDD and 1950 (8.3%) by controls.





Conclusions

 Employees with major depressive disorder utilize a variety of paid and unpaid leaves approximately three times more than controls.

References

- 1 Goetzel RH, et al. J Occup Environ Med. 2003 Jan;45(1):5-14
- 2 Fact Sheet #28: The Family and Medical Leave Act. https://www.dol.gov/agencies/whd/fact-sheets/28-fmla
- 3 Brook RA, et al. *Mental Health Clinician* (2021) 11 (5): 279–286.
- 4 Brook RA, et al. *J Oncol Res Ther* 7: 10142.
- 5 Brook RA, et al. Am Health Drug Benefits. 2023 [Web Exclusive]
- 6 Kleinman NL, et al. *J Occup Environ Med*. 2013;55(3):240. 7 Gardner HH, et al. *J Clin Psychiatry*. 2006;67(8):1209-18.
- 8 Brook RA, et al. *Am J Manag Care*. 2007;13(4):179-86.
- 9 Brook RA, et al. *Postgrad Med*. 2015 Jun;127(5):455-62.
- 10 Hersh CM, et al. *J Med Econ*. 2021;24(1):479-486.
- 11 Kuvadia H, et al. *Prim Care Companion CNS Disord*. 2021;12;23(4):20m02893.
- 12 Kleinman NL, et al. *Ann Allergy Asthma Immunol*. 2009; 103(2):114-20.
- 13 Brook RA, et al. *Am Health Drug Benefits*. 2018;11(8):396-403.
- 14 Brook RA, et al. *J Oncol Res Ther* 7: 10143.
- 15 Hendin B, et al. *J Health Econ Outcomes Res.* 2023 Apr 13; 10(1):91-101.





